Gilead licenses Assembly Bio's investigational Herpes drugs after positive phase 1b data
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
The receipt of this order further strengthens the company's position in the global pharmaceutical market
Most recently, Yuvraj was the Director of Operations, Business Development & Process Excellence at Zeon Lifesciences Ltd
Total income for the period stood at Rs. 7101.28 crore
The company has introduced an innovative Dual Release Proton Pump Inhibitor (PPI) tablet, a next-generation therapy for patients suffering from moderate to severe or treatment resistant gastroesophageal reflux disease
The HCl gas is generated continuously which is absorbed in the water scrubber using a chilled falling film system
Sun Pharma's Halol plant gets OAI classification from US FDA inspection
Mangalam Drugs and Organics receives repeat export order worth $ 21, 81,040
Subscribe To Our Newsletter & Stay Updated